🍬 Postpartum Glucose Normalization & Type 2 Diabetes Risk Simulator

Placental Hormone Withdrawal at Delivery

Delivery of the placenta abruptly ends pregnancy-related insulin resistance.

• hPL: Key hormone drop (Placental lactogen removed)
• Minutes: Onset (After placental delivery)
• ↓ Sharp: Insulin resistance (Rapid reversal begins)
• ~7%: GDM prevalence (Of pregnancies (illustrative))

Mechanism of hormone withdrawal

Placenta removal ends hPL, progesterone, and cortisol-driven resistance.

Placeholder: hormone clearance drives rapid metabolic shift postpartum.

Glucose Normalization Within Days

Maternal glycemia typically returns toward normal within days after birth.

• 1–3 days: Normalization window (Typical postpartum course)
• ↓ Fast: Insulin needs (Often below pre-pregnancy levels)
• ~10–15%: Persistent hyperglycemia (Illustrative fraction)
• Fasting glucose: Monitoring (Inpatient check)

Early postpartum glucose course

Placeholder: glucose curve trends down toward the normal band quickly.

Placeholder: most patients normalize before hospital discharge.

6-Week Postpartum OGTT Retest

A 75g oral glucose tolerance test at 6 weeks reclassifies glucose status.

• 6 weeks: Test timing (Postpartum standard)
• 75g OGTT: Test type (2-hour test)
• ~15–20%: Abnormal result (Illustrative rate)
• ~2–5%: Reclassified as T2D (Illustrative rate)

Purpose of the retest

Placeholder: the 6-week OGTT distinguishes normal, prediabetes, and diabetes.

Placeholder: early retest catches persistent glucose abnormality.

Long-Term Type 2 Diabetes Risk

Cumulative type 2 diabetes risk after GDM can reach up to about 50%.

• Up to 50%: 10-year cumulative risk (Illustrative ceiling)
• ~7–10×: Risk vs. no GDM (Relative risk, illustrative)
• 5–10 yrs: Peak risk window (Post-pregnancy)
• ~30–50%: Lifestyle mitigation (Illustrative reduction)

Trajectory of long-term risk

Placeholder: risk climbs steadily over years without intervention.

Placeholder: adherence to lifestyle change meaningfully lowers risk.

Annual Screening Recommendation

Annual or periodic glucose screening is recommended for years after GDM.

• Annual: Recommended interval (Or every 1–3 years)
• FPG/A1c/OGTT: Test options (Clinician choice)
• Lifelong: Duration (Ongoing monitoring)
• Diet + exercise: Counseling (Standard advice)

Screening cadence guidance

Placeholder: regular screening enables earlier detection and intervention.

Placeholder: annual screening plus lifestyle change is the core recommendation.